Advitech announces a definitive distribution agreement of Dermylex(TM) for France and Belgium


    QUEBEC, June 27 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) announced today the conclusion of a
Definitive Agreement (the "Agreement") for the distribution of Dermylex(TM) in
France and Belgium with Iprad Santé S.A., a pharmaceutical corporation
specialized in the development and commercialization of dermatological and
gynecological products.
    As per the Agreement, it is expected that the distribution of
Dermylex(TM), in these two countries, will begin in the third quarter of 2007.
Dermylex(TM) will be available in a network of more than 22,000 drugstores
across France and Belgium. A promotional launch activity was held in Paris,
France at the 2nd International Congress on Psoriasis, from June 22nd to
June 24th 2007. During this congress, Dr Patrice Poubelle MD, D.Sc presented
Dermylex(TM) in one of the congress' workshop.
    "This agreement, as stated in a previous press release on April 5, 2007,
is important for Advitech on two fronts: it sets up the first commercial
partnership with a pharmaceutical company whose focus is dermatology and,
secondly, validates Dermylex(TM) technological platform and clinical program
following a thorough due diligence by Iprad" commented Mr. Renaud Beauchesne,
president and chief executive officer of Advitech. "With this agreement for
the French and Belgian markets, added to last week's partnership announcement
with Thorne Research and Diversified Natural Product for the U.S. market,
Advitech is now active in two of the most important markets for dermatological
products. Our sales will benefit, in the near future, from these important
partnerships" added Renaud Beauchesne.
    Mr. Pierre-Marie Defrance, president and chairman of Iprad Group, added:
"There is a new interest from psoriasis patients for products like  
Dermylex(TM) and, after analysis by our experts of the scientific and
technical documentation available on Dermylex(TM), we are confident to
effectively position Dermylex(TM) in the French and Belgian dermatologic
markets". Iprad Santé employs 105 medical visitors and 32 commercial

    About Iprad Santé S.A.

    Iprad Group consists of two different business units: Iprad Laboratory
develops pharmaceutical products and Iprad Santé commercializes pharmaceutical
products and food supplements for the Iprad Group. Iprad Santé S.A. employs on
the French and Belgian territories 105 medical visitors and 32 commercial
representatives. Their main products target the dermatological and
gynecological markets and they have generated, in 2006, sales of more than
40 million Euros. Iprad Group has experienced a strong growth over the past
ten years and it intends to maintain this growth by adding up products
specific to dermatology.

    About Advitech Inc.

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease.

    About Dermylex(TM)

    Dermylex(TM) developed by Advitech, is an oral natural health product
relieving mild-to-moderate psoriasis symptoms. Two clinical trials, one of
them multi-center, double-blind and placebo-controlled, for 112 days and on 84
patients, clinically proved the efficacy and safety of Dermylex(TM) for
mild-to-moderate psoriasis. Dermylex(TM) is currently available in Canada.

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The TSX Venture Exchange does not
accept responsibility for the adequacy or accuracy of this release.

For further information:

For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498 ext. 228,; Serge Comeau, Investor's relations, (514)862-4160;

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890